Pfizer submits data to FDA as it seeks to use COVID vaccine in children aged 5-11
Pfizer and BioNTech announced Tuesday they have submitted data to the U.S. Food and Drug Administration (FDA) from the Phase 2/3 trial of their COVID-19 vaccine in children 5 to 11 years of age.